Magazine
Sign up for your free subscription and keep up-to-date.
Upcoming Events
Newsletters
Stay updated on the latest news and technologies with Bioscienceworld's newsletters.
Five to choose from.
To Market
|
July 13 2007
BIOTECanada product launch stewardship policy for agricultural biotechnology BIOTECanada announces the adoption of a new Product Launch Stewardship Policy for agricultural biotechnology, encouraging its members to facilitate the flow of goods in commerce and minimize the potential for trade disruptions with respect to products of agricultural biotechnology.
|
|
July 13 2007
ARIUS announces second quarter fiscal 2007 financial results ARIUS Research Inc. releases its financial and operational results for the second quarter, ended May 31, 2007.
|
|
July 03 2007
Amorfix announces 2007 year end results Amorfix Life Sciences announces its operational and financial results for the year ended March 31, 2007, as well as financial results for the fourth quarter.
|
|
June 18 2007
Amorfix receives ISO13485 certification Amorfix Life Sciences has achieved ISO13485:2003 certification for its in vitro diagnostic EP-vCJD TM test for detection of aggregated misfolded proteins in variant Creutzfeldt-Jacob Disease (vCJD).
|
|
June 08 2007
Amendments made to Intellectual Property Regulations benefit universities and businesses The Canadian Intellectual Property Office (CIPO) announces the coming into force of regulatory amendments, effective immediately, ensuring Canada's intellectual property (IP) regime is more user-friendly, cost-effective and responsive to the needs of Canadian universities and businesses.
|
|
June 04 2007
Protox reports 2006 financial results and achievements Protox reports it has completed 2006 with cash resources of $9,977,259 and a working capital of $8,918,615. Subsequently, the company also raised an additional $583,000 from the exercise of outstanding share purchase warrants.
|
|
May 22 2007
Allon Therapeutics releases first quarter operating results Allon Therapeutics Inc. releases its first quarter operating results, announcing that the company remains on track to achieve all of its 2007 milestones, including initiating a third Phase II human clinical trial.
|
|
May 22 2007
Med BioGene Inc. reports financial results for 2006 Med BioGene Inc. (MBI) reports its financial results for 2006, with recent scientific and business highlights.
|
|
May 17 2007
U of S researcher awarded $242,000 for potential new anti-inflammatory drug University of Saskatchewan health researcher John Gordon has been awarded $242,000 from the Canadian Institutes of Health Research (CIHR) to help bring closer to market a new anti-inflammatory drug that could ease the suffering of people with arthritis, inflammatory bowel disease and cystic fibrosis, as well as reduce damage caused by heart attacks and strokes.
|
|
May 16 2007
How can Canada survive in a globally-driven pharmaceutical market? Canada is a big, big country in size. Its neighbour, the USA, is 5% smaller and yet holds 10 times the population. Eighty percent of Canadians live within 200 km of the USA border, which perhaps says a lot about the attitude of Canadian economic dependence that exists.
|
|
May 16 2007
Perspective Commercialization of genomics over the past 10 years One of the great expectations of genomics in the 1990s was that it would radically and directly improve the business of drug discovery.
|
|
May 11 2007
BioNova heads up Atlantic Canada delegation to BIO 2007 Over 40 people representing Nova Scotia's life sciences industry were in Boston last week to take part in the world's largest biotechnology conference and showcase. The BIO convention, which draws over 20,000 delegates and almost 1,800 exhibitors, was another huge success as BioNova headed up the Atlantic Canada delegation.
|
|
April 25 2007
Warnex reviewing strategic options to enhance shareholder value Warnex Inc. has initiated a review of various strategic options for its ongoing laboratory services business in order to enhance shareholder value. These options include, but are not limited to, partnerships, mergers or the sale of the company.
|
|
April 23 2007
Agilent receives Growth Strategy Leadership award Agilent Technologies is awarded the 2006 Frost & Sullivan Growth Strategy Leadership award for the European Gene Expression market.
|
|
April 18 2007
Timing Your Freedom to Operate Analysis to Maximize Your Benefits By France Côté and Marie-Éve Bérubé-Côté
A patent provides its owner with the right to exclude others from commercializing a product covered, in part or in whole, by the patent. |
|
March 23 2007
First shelf stable juice to contain Omega-3 from fish oil hits the market Ocean Nutrition Canada Limited (ONC), supplier of MEG-3 brand Omega-3 EPA/DHA food and dietary supplement ingredients, announces that A. Lassonde Inc. has launched the first shelf stable juice containing MEG-3 healthy food ingredient throughout Canada. Not only is this the first shelf stable juice to contain MEG-3, but it is also the first shelf stable juice to contain Omega-3 from fish oil.
|
|
February 23 2007
Shoppers Drug Mart launches Halifax drug company to national status Origin BioMed Inc., a manufacturer of over-the-counter topical drug products, launches its lead product Neuragen, into one of Canada's most successful drug store chain, Shoppers Drug Mart. Neuragen is a topical oil for rapid relief of diabetic and post-shingles pain, targeting the $4 billion neuropathic pain market.
|
|
February 22 2007
Neptune Technologies & Bioressources Inc. appoints VP Business Neptune Technologies and Bioressources announces that Thierry Houillon, recently appointed member of Neptune's Board of Directors and previous CEO of Danone Canada, has joined Neptune as the vice president, Business Development, Functional Food. The appointment of Houillon will complete Neptune's executive force as the Company prepares for the upcoming penetration of the functional food market foreseen short term.
|
|
February 12 2007
BioGasoline coming soon Global Clean Energy Corp is concerned about the current and future state of the global environment. It is excited that BioDiesel is being created and used worldwide. Now for the next phase, BioGasoline. Gasoline (Petrol) usage is even greater worldwide and its new product will lower the dependence on fossil fuels, the dependence on the Middle East and help farmers worldwide.
|
|
February 12 2007
Nuvo's communications are ongoing with FDA Nuvo Research Inc. provides an update on discussions with the U.S. Food and Drug Administration regarding the approvable letter issued by the FDA for Pennsaid, a non-steroidal anti-inflammatory drug (NSAID) used for the treatment of osteoarthritis.
|
|
February 01 2007
Bioniche receives approval to distribute E.coli vaccine The Canadian Food Inspection Agency (CFIA) has granted Bioniche Life Sciences Inc. authorization to distribute its E. coli O157:H7 cattle vaccine to Canadian veterinarians under a Permit to Release Veterinary Biologics.
|
|
February 01 2007
Squire to market Nuvo's Pennsaid Plus Squire Pharmaceuticals Inc., a subsidiary of Paladin Labs Inc. will market and sell PennsaidR Plus in Canada following a licensing agreement with Nuvo Research Inc.
|
|
January 10 2007
NRC gives start-ups a 'functional' step up To help western Canadian nutraceutical, functional food and natural health companies survive their early years, the National Research Council of Canada (NRC) has opened a BioAccess Commercialization Centre in Saskatoon, SK.
|
|
January 10 2007
Former Olympic skier to pitch Advitech drug Former Canadian Olympian Pierre Harvey will serve as the face for Quebec City, QC.-based Advitech Inc.'s psoriasis remedy DermylexTM.
|
|
January 09 2007
ART announces extension of current eXplore Optix distribution agreement with GE Healthcare Advanced Research Technologies Inc (ART), a Canadian medical device company and a leader in optical molecular imaging products for the healthcare and pharmaceutical industries, announces the extension of its current agreement with GE Healthcare for the exclusive worldwide distribution of its eXplore Optix preclinical optical molecular imaging system.
|
|
December 18 2006
Warnex explores strategic alternatives for its pathogen detection business Warnex Inc. announces that it has decided to explore strategic alternatives for its pathogen detection business including partnerships, joint ventures or the sale of this business, in order to enhance shareholder value. The Company has mandated a U.S.-based investment banking firm, Kirchner & Company, Inc., to act as its agent in this
process. |
|
November 27 2006
Oridis Biomed Signs License Agreement Oridis Biomed has signed a license agreement with the National Institutes of Health (NIH) for the worldwide commercial use of NIH's proprietary Tissue Micro-Array (TMA) technology.
|
|
November 27 2006
NRC launches BioAccess commercialization centre The National Research Council of Canada (NRC) officially opened a new BioAccess Commercialization Centre in Saskatoon this morning. The Centre was created by NRC to assist innovative firms in Western Canadas nutraceutical, functional food and natural health products industries bring products to market and stake a claim in the lucrative $150 billion global market.
|
|
November 07 2006
Agence de la sante et des services sociaux contracts MediSolution Ltd. The Agence de la sante et des services sociaux de la Mauricie et du Centre-du-Quebec has contracted MediSolution Ltd.
|
|
September 19 2006
Monsanto Canada Launches New Soybean Line Monsanto Canada Inc. has launched the Vistive soybean, part of the company's Dekalb® brand.
|
|
September 11 2006
Regulatory Approval Sought for Cancer Wex Pharmaceuticals Inc. has requested a meeting with regulatory authorities to pursue the development of tetrodotoxin (TTX).
|
|
August 10 2006
Health Canada Green-Lights Rheumatoid Arthritis Drug Health Canada has approved Mississauga, Ont.-based Hoffmann-La Roche Ltd.s Rituxan® (rituximab) in combination with methotrexate.
|
|
August 09 2006
HIV Test Receives European Approval BioLytical Laboratories Inc. has received European approval for a rapid HIV antibody test.
|
|
July 05 2006
Cholesterol-Lowering Cheese Sold In U.K. U.K. retailer ASDA, a subsidiary of Wal-Mart, has introduced Heartfelt Plus Natural Cheese, a cheddar that contains Forbes Medi-Tech Inc.'s (Vancouver, BC) cholesterol-lowering ingredient Reducol.
|
|
June 12 2006
CellCept Receives Orphan Drug Designation The U.S. Food and Drug Administration has granted Aspreva Pharmaceuticals Corp. (Victoria, BC) and F. Hoffman-La Roche Ltd. (Basel, Switzerland) orphan drug designation for CellCept® in the treatment of pemphigus vulgaris, an autoimmune disease that causes painful skin blistering.
|
|
March 20 2006
Prostate Cancer Implant Approved Health Canada has approved Paladin Labs Inc.'s (Montreal, QC) once-yearly luteinizing hormone-releasing hormone (LHRH) implant Vantas®, used for palliative treatment of advanced prostate cancer.
|
|
March 02 2006
Amorfix Obtains Worldwide Protein Licence Drug therapy and diagnostics company Amorfix Life Sciences Ltd. (Toronto, ON) has obtained worldwide licence to superoxide dismutase-1 (SOD1), a protein known to misfold and aggregate in patients with amyotrophic lateral sclerosis (ALS), otherwise known as Lou Gehrig's disease.
|
|
February 06 2006
SoySuperb to be Launched in U.S. Winnipeg-based Brett-Young Seeds has announced the spring 2006 introduction of its SoySuperb soybean growth promoter into the U.S. market.
|
|
January 01 2006
Laser Treatment Approved in Canada Ondine Biopharma Corp.'s (Vancouver, BC) photoactivated disinfection system, Periowave, has been approved by Health Canada.
|
|
January 01 2006
FDA Approves Adherexs Chemotherapy-enhancing Drug Adherex Technologies Inc.'s (Ottawa, ON) Investigational New Drug (IND) application for eniluracil has been approved by the U.S. Food and Drug Administration.
|
|
July 29 2005
Twinstrand Gains FDA Approval of IND The U.S. Food and Drug Administration (FDA) has granted Burnaby, B.C.-based Twinstrand Therapeutics Inc. approval for its Investigational New Drug application for clinical development of TST10088.
|
|
June 14 2005
Post-marketing Observational Studies by John Sampalis, PhD Providing insight into real-life clinical practice regarding safety, efficacy and patients drug compliance.
|
|
May 30 2005
Magistral Biotech's Libracol® Approved by Health Canada Montreal, Que.-based Magistral Biotech Inc. has been granted a Natural Product Number (NPN) from Health Canada for its cholesterol-reducing product Libracol®.
|
|
May 10 2005
Market Access Planning for Emerging Medical Technology: Health Technology Assessments By Jacqueline Csonka-Peeren Medical device manufacturers looking to commercialize emerging medical technology need to consider not only strategies for intellectual property protection and regulatory approval, but also for technology diffusion, or market access. Planning for market access can help accelerate sales growth, economies of scale and brand recognition.
|
|
May 10 2005
The VC Vista Compiled by Deborah Komlos Industry Views on Canadian Biotech Financings for 2005-06
|
|
April 12 2005
Bextra Withdrawn From North American Market Pfizer Inc. (New York, NY), makers of the recently maligned arthritis drug Bextra®, has agreed to pull the product off the market in Canada and the United States.
|
|
February 08 2005
Fork in the Road By Amber Lepage-Monette Navigating the various routes to commercialization can be tricky, when companies are faced with a multitude of approaches that may very well differ from year to year and product to product.
|
|
January 17 2005
Labopharm Receives French Approval for Pain Medication Laval, Que.-based Labopharm Inc. has received French regulatory approval for its once-daily formulation of tramadol, used to treat moderate and severe pain.
|
|
September 20 2004
ID Biomedical Supplies Government With Vaccine The Government of Canada has selected ID Biomedical Corp. (Vancouver, BC) as its supplier of meningitis C vaccine for the next two years.
|
|
September 20 2004
The IPO window: who will follow MethylGene? By Patricia Nicholson The fourth quarter of 2003 and the first half of 2004 saw a surge in biotech IPOs in the United States, and led to speculation that the Canadian IPO window might be opening for the first time in several years. The biotech industry turned its eyes to MethylGene Inc. (Montreal, QC), which completed a much-anticipated initial public offering in June.
|